Independent FDA Analyses of Nirmatrelvir/Ritonavir Resistance in the Phase 2/3 Trials EPIC-HR and EPIC-SR.
- Published in:
- Clinical Infectious Diseases, 2025, v. 80, n. 5, p. 1005, doi. 10.1093/cid/ciae615
- By:
- Publication type:
- Article
Works matching AU Rawson, Jonathan M O
Results: 9
1
2
Recombination is required for efficient HIV-1 replication and the maintenance of viral genome integrity.
- Published in:
- Nucleic Acids Research, 2018, v. 46, n. 20, p. 10535, doi. 10.1093/nar/gky910
- By:
- Publication type:
- Article
3
Elements in the 5′ Untranslated Region of Viral RNA Important for HIV Gag Recognition and Cross-Packaging.
- Published in:
- Viruses (1999-4915), 2025, v. 17, n. 4, p. 551, doi. 10.3390/v17040551
- By:
- Publication type:
- Article
4
Development of a Cell-Based Luciferase Complementation Assay for Identification of SARS-CoV-2 3CL pro Inhibitors.
- Published in:
- Viruses (1999-4915), 2021, v. 13, n. 2, p. 173, doi. 10.3390/v13020173
- By:
- Publication type:
- Article
5
Retroviral Vectors for Analysis of Viral Mutagenesis and Recombination.
- Published in:
- Viruses (1999-4915), 2014, v. 6, n. 9, p. 3612, doi. 10.3390/v6093612
- By:
- Publication type:
- Article
6
HIV-1 and HIV-2 exhibit similar mutation frequencies and spectra in the absence of G-to-A hypermutation.
- Published in:
- Retrovirology, 2015, v. 12, n. 1, p. 1, doi. 10.1186/s12977-015-0180-6
- By:
- Publication type:
- Article
7
HIV‑1 and HIV‑2 exhibit similar mutation frequencies and spectra in the absence of G‑to‑A hypermutation.
- Published in:
- Retrovirology, 2015, v. 12, n. 1, p. 60, doi. 10.1186/s12977-015-0180-6
- By:
- Publication type:
- Article
8
Uses and Challenges of Antiviral Polyclonal and Monoclonal Antibody Therapies.
- Published in:
- Pharmaceutics, 2023, v. 15, n. 5, p. 1538, doi. 10.3390/pharmaceutics15051538
- By:
- Publication type:
- Article
9
Evaluation of SARS-CoV-2 RNA Rebound After Nirmatrelvir/Ritonavir Treatment in Randomized, Double-Blind, Placebo-Controlled Trials--United States and International Sites, 2021-2022.
- Published in:
- MMWR: Morbidity & Mortality Weekly Report, 2023, v. 72, n. 51, p. 1365, doi. 10.15585/mmwr.mm7251a2
- By:
- Publication type:
- Article